MARKET

ABEO

ABEO

Abeona
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.420
-0.010
-0.41%
After Hours: 2.420 0 0.00% 16:00 11/21 EST
OPEN
2.440
PREV CLOSE
2.430
HIGH
2.490
LOW
2.330
VOLUME
178.52K
TURNOVER
--
52 WEEK HIGH
9.55
52 WEEK LOW
1.460
MARKET CAP
123.55M
P/E (TTM)
-1.5217
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ABEO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ABEO News

  • ABEO ALERT: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Abeona Therapeutics Inc. ABEO
  • GlobeNewswire.10h ago
  • Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zendesk, PG&E Corporation, Sealed Air, and Abeona and Encourages Investors to Contact the Firm
  • GlobeNewswire.1d ago
  • Class Action Notification - Abeona Therapeutics Inc. (ABEO), AZZ, Inc. (AZZ) & Bloom Energy Corporation (BE) - Bronstein, Gewirtz & Grossman, LLC
  • ACCESSWIRE.1d ago
  • INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  • ACCESSWIRE.1d ago

More

Industry

Biotechnology & Medical Research
-0.31%
Pharmaceuticals & Medical Research
+0.32%

Hot Stocks

Name
Price
%Change

About ABEO

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
More

Webull offers Abeona Therapeutics Inc (ABEO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.